SP100 and primary biliary cholangitis: In the ANA category, research has shown that antinuclear dot antibodies sp100 and antinuclear pore antibodies gp210 are specific biomarkers in PBC serum (9, 14, 15), and they can reduce AMA-negative cases by less than 5% in PBC (16).